The consequence is that if you were to collapse the country list into one, without distinguishing between the requirements or the manufacturing capacity of different countries, what you would potentially see is the ability to have a compulsory licence to send products to countries that are well developed, or that have their own pharmaceutical manufacturing capacity, in situations where there's no emergency. Mexico would be on the list. Singapore would be on the list. I think India is on the list as well.
On October 28th, 2010. See this statement in context.